Immunosuppression minimization vs. complete drug withdrawal in liver transplantation

Journal of Hepatology

Volumn 59, Issue 4, 2013, Pages 872-879

  Londoño, Maria Carlota ^a   Rimola, Antoni ^a   O'Grady, John ^b   Sanchez Fueyo, Alberto ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Immunosuppression minimization Immunosuppression withdrawal Liver transplantation

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADVERSE OUTCOME; ARTICLE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MONOTHERAPY; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ANTI-THYMOCYTE GLOBULIN; ATG; CALCINEURIN INHIBITOR; CNI; HCV; HEPATITIS C VIRUS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSION MINIMIZATION; IMMUNOSUPPRESSION WITHDRAWAL; IS; LIVER TRANSPLANTATION; MAMMALIAN TARGET OF RAPAMYCIN; MMF; MOFETIL MYCOPHENOLATE; MTOR; RANDOMIZED CLINICAL TRIAL; RCT; REPROGRAMMING THE IMMUNE SYSTEM FOR THE ESTABLISHMENT OF TOLERANCE; RISET; UNITED STATES; US;

CALCINEURIN; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LYMPHOCYTE DEPLETION; MYCOPHENOLIC ACID; STEROIDS; T-LYMPHOCYTES; TOR SERINE-THREONINE KINASES;

EID: 84884414991     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.04.003     Document Type: Note

References (78)

1. European Liver Transplant Registry. Data analysis booklet; 2012. Available at: http://www.eltr.org.
2. R.I. Lechler, M. Sykes, A.W. Thomson, and L.A. Turka Organ transplantation - how much of the promise has been realized? Nat Med 11 2005 605 613 (Pubitemid 40868300)
3. J.P. Soulillou, and M. Giral Controlling the incidence of infection and malignancy by modifying immunosuppression Transplantation 72 2001 S89 S93
4. N.J. London, S.M. Farmery, E.J. Will, A.M. Davison, and J.P. Lodge Risk of neoplasia in renal transplant patients Lancet 346 1995 403 406
5. J. Dantal, and J.P. Soulillou Immunosuppressive drugs and the risk of cancer after organ transplantation N Engl J Med 352 2005 1371 1373 (Pubitemid 40411505)
6. T.A. Gonwa, M.L. Mai, L.B. Melton, S.R. Hays, R.M. Goldstein, and M.F. Levy End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment Transplantation 72 2001 1934 1939 (Pubitemid 34027867)
7. M. Hojo, T. Morimoto, M. Maluccio, T. Asano, K. Morimoto, and M. Lagman Cyclosporine induces cancer progression by a cell-autonomous mechanism Nature 397 1999 530 534
8. J. Romagnoli, F. Citterio, P. Violi, F. Cadeddu, G. Nanni, and M. Castagneto Post-transplant diabetes mellitus: a case-control analysis of the risk factors Transpl Int 18 2005 309 312 (Pubitemid 41726894)
9. R.H. Wiesner, and J.J. Fung Present state of immunosuppressive therapy in liver transplant recipients Liver Transpl 17 2011 S1 S9
10. M. Rodriguez-Peralvarez, G. Germani, V. Papastergiou, E. Tsochatzis, E. Thalassinos, T.V. Luong, and N Rolando Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome J Hepatol 58 2013 262 270
11. A.O. Ojo, P.J. Held, F.K. Port, R.A. Wolfe, A.B. Leichtman, and E.W. Young Chronic renal failure after transplantation of a nonrenal organ N Engl J Med 349 2003 931 940 (Pubitemid 37064766)
12. M. Nowicki, and R. Zwiech Chronic renal failure in non-renal organ transplant recipients Ann Transplant 10 2005 54 58
13. A. Sanchez-Fueyo Hot-topic debate on tolerance: immunosuppression withdrawal Liver Transpl 17 2011 S69 S73
14. J. Lerut, and A. Sanchez-Fueyo An appraisal of tolerance in liver transplantation Am J Transplant 6 2006 1774 1780 (Pubitemid 44024949)
15. G. Orlando Finding the right time for weaning off immunosuppression in solid organ transplant recipients Exp Rev Clin Immunol 6 2010 879 892
16. T.E. Starzl, N. Murase, K. Abu-Elmagd, E.A. Gray, R. Shapiro, and B. Eghtesad Tolerogenic immunosuppression for organ transplantation Lancet 361 2003 1502 1510 (Pubitemid 36566340)
17. R. Calne, P. Friend, S. Moffatt, A. Bradley, G. Hale, and J. Firth Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients Lancet 351 1998 1701 1702 (Pubitemid 28254534)
18. A. Marcos, B. Eghtesad, J.J. Fung, P. Fontes, K. Patel, and M. Devera Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus Transplantation 78 2004 966 971 (Pubitemid 39391856)
19. N. De Ruvo, A. Cucchetti, A. Lauro, M. Masetti, N. Cautero, and F. Di Benedetto Preliminary results of a "prope" tolerogenic regimen with thymoglobulin pretreatment and hepatitis C virus recurrence in liver transplantation Transplantation 80 2005 8 12 (Pubitemid 40980888)
20. C.E. Benitez, I. Puig-Pey, M. Lopez, M. Martinez-Llordella, J.J. Lozano, and F. Bohne ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation Am J Transplant 10 2010 2296 2304
21. V. Donckier, L. Craciun, V. Lucidi, A. Buggenhout, R. Troisi, and X. Rogiers Acute liver transplant rejection upon immunosuppression withdrawal in a tolerance induction trial: potential role of IFN-gamma-secreting CD8+ T cells Transplantation 87 2009 S91 S95
22. M. Rodriguez-Peralvarez, G. Germani, T. Darius, J. Lerut, E. Tsochatzis, and A.K. Burroughs Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis Am J Transplant 12 2012 2797 2814
23. G. Sgourakis, A. Radtke, I. Fouzas, S. Mylona, K. Goumas, and I. Gockel Corticosteroid-free immunosuppression in liver transplantation: a meta-analysis and meta-regression of outcomes Transpl Int 22 2009 892 905
24. D.N. Samonakis, M. Mela, A. Quaglia, C.K. Triantos, U. Thalheimer, and G. Leandro Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy in liver transplant recipients with hepatitis C virus cirrhosis Transpl Infect Dis 8 2006 3 12
25. J. Lerut, J. Mathys, C. Verbaandert, S. Talpe, O. Ciccarelli, and J. Lemaire Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study Ann Surg 248 2008 956 967
26. C. Margarit, I. Bilbao, L. Castells, I. Lopez, L. Pou, and E. Allende A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C Transpl Int 18 2005 1336 1345 (Pubitemid 41726729)
27. J.I. Herrero, J. Quiroga, B. Sangro, M. Girala, N. Gomez-Manero, and F. Pardo Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil Liver Transpl Surg 5 1999 414 420 (Pubitemid 29437019)
28. H.J. Schlitt, A. Barkmann, K.H. Boker, H.H. Schmidt, N. Emmanouilidis, and J. Rosenau Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study Lancet 357 2001 587 591 (Pubitemid 32179611)
29. G.P. Pageaux, L. Rostaing, Y. Calmus, C. Duvoux, C. Vanlemmens, and J. Hardgwissen Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation Liver Transpl 12 2006 1755 1760 (Pubitemid 44920019)
30. G. Orlando, L. Baiocchi, A. Cardillo, G. Iaria, N. De Liguori Carino, and L. De Luca Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension Liver Transpl 13 2007 46 54 (Pubitemid 46099973)
31. V. Schmitz, S. Laudi, F. Moeckel, G. Puhl, M. Stockmann, and Z.V. Tran Chronic renal dysfunction following liver transplantation Clin Transpl 22 2008 333 340 (Pubitemid 351689664)
32. S. Shenoy, K.L. Hardinger, J. Crippin, N. Desai, K. Korenblat, and M. Lisker-Melman Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial Transplantation 83 2007 1389 1392 (Pubitemid 46800318)
33. K.D. Fairbanks, J.A. Eustace, D. Fine, and P.J. Thuluvath Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus Liver Transpl 9 2003 1079 1085 (Pubitemid 37304464)
34. D. DuBay, R.J. Smith, K.G. Qiu, G.A. Levy, L. Lilly, and G. Therapondos Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens Liver Transpl 14 2008 651 659 (Pubitemid 351696277)
35. C.J. Watson, A.E. Gimson, G.J. Alexander, M.E. Allison, P. Gibbs, and J.C. Smith A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function Liver Transpl 13 2007 1694 1702
36. M.F. Abdelmalek, A. Humar, F. Stickel, P. Andreone, A. Pascher, and E. Barroso Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial Am J Transplant 12 2012 694 705
37. G.J. McKenna, and J.F. Trotter Sirolimus conversion for renal dysfunction in liver transplant recipients: the devil really is in the details Am J Transplant 12 2012 521 522
38. P. De Simone, H.J. Metselaar, L. Fischer, J. Dumortier, K. Boudjema, and J. Hardwigsen Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial Liver Transpl 15 2009 1262 1269
39. L. Fischer, J. Klempnauer, S. Beckebaum, H.J. Metselaar, P. Neuhaus, and P. Schemmer A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation - PROTECT Am J Transplant 12 2012 1855 1865
40. P. De Simone, F. Nevens, L. De Carlis, H.J. Metselaar, S. Beckebaum, and F. Saliba Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial Am J Transplant 12 2012 3008 3020
41. M. Battaglia, A. Stabilini, and M.G. Roncarolo Rapamycin selectively expands CD4+ CD25+ FoxP3+ regulatory T cells Blood 105 2005 4743 4748 (Pubitemid 40807298)
42. J. Levitsky, J.M. Mathew, M. Abecassis, A. Tambur, J. Leventhal, and D. Chandrasekaran Systemic immunoregulatory and proteogenomic effects of tacrolimus to sirolimus conversion in liver transplant recipients Hepatology (Baltimore, Md.) 57 2013 239 248
43. J. Levitsky, L. Gallon, J. Miller, A.R. Tambur, J. Leventhal, and C. Flaa Allospecific regulatory effects of sirolimus and tacrolimus in the human mixed lymphocyte reaction Transplantation 91 2011 199 206
44. S.G. Hubscher What is the long-term outcome of the liver allograft? J Hepatol 55 2011 702 717
45. M. Sebagh, K. Rifai, C. Feray, F. Yilmaz, B. Falissard, and B. Roche All liver recipients benefit from the protocol 10-year liver biopsies Hepatology (Baltimore, Md.) 37 2003 1293 1301 (Pubitemid 36667308)
46. O. Pappo, H. Ramos, T.E. Starzl, J.J. Fung, and A.J. Demetris Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation Am J Surg Pathol 19 1995 192 206
47. G.I. Slapak, R. Saxena, B. Portmann, E. Gane, J. Devlin, and R. Calne Graft and systemic disease in long-term survivors of liver transplantation Hepatology (Baltimore, Md.) 25 1997 195 202 (Pubitemid 27015010)
48. T.E. Starzl, A.J. Demetris, M. Trucco, N. Murase, C. Ricordi, and S. Ildstad Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance Hepatology (Baltimore, Md.) 17 1993 1127 1152 (Pubitemid 23187422)
49. J. Ashton-Chess, M. Giral, S. Brouard, and J.P. Soulillou Spontaneous operational tolerance after immunosuppressive drug withdrawal in clinical renal allotransplantation Transplantation 84 2007 1215 1219 (Pubitemid 351339307)
50. G.V. Mazariegos, J. Reyes, I.R. Marino, A.J. Demetris, B. Flynn, and W. Irish Weaning of immunosuppression in liver transplant recipients Transplantation 63 1997 243 249 (Pubitemid 27121206)
51. J. Devlin, D. Doherty, L. Thomson, T. Wong, P. Donaldson, and B. Portmann Defining the outcome of immunosuppression withdrawal after liver transplantation Hepatology 27 1998 926 933 (Pubitemid 28160476)
52. R. Girlanda, M. Rela, R. Williams, J.G. O'Grady, and N.D. Heaton Long-term outcome of immunosuppression withdrawal after liver transplantation Transplant Proc 37 2005 1708 1709 (Pubitemid 40790804)
53. M. Takatsuki, S. Uemoto, Y. Inomata, S. Sakamoto, M. Hayashi, and M. Ueda Analysis of alloreactivity and intragraft cytokine profiles in living donor liver transplant recipients with graft acceptance Transpl Immunol 8 2001 279 286 (Pubitemid 32249016)
54. J.D. Eason, A.J. Cohen, S. Nair, T. Alcantera, and G.E. Loss Tolerance: is it worth the risk? Transplantation 79 2005 1157 1159 (Pubitemid 40664015)
55. P. Tryphonopoulos, A.G. Tzakis, D. Weppler, R. Garcia-Morales, T. Kato, and J.R. Madariaga The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation Am J Transplant 5 2005 608 613 (Pubitemid 40313354)
56. G. Tisone, G. Orlando, A. Cardillo, G. Palmieri, T.M. Manzia, and L. Baiocchi Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence J Hepatol 44 2006 702 709
57. N. Assy, P.C. Adams, P. Myers, V. Simon, G.Y. Minuk, and W. Wall Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid Transplantation 83 2007 1571 1576 (Pubitemid 46987908)
58. J.A. Pons, B. Revilla-Nuin, A. Baroja-Mazo, P. Ramirez, L. Martinez-Alarcon, and F. Sanchez-Bueno FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal Transplantation 86 2008 1370 1378
59. T. Koshiba, Y. Li, M. Takemura, Y. Wu, S. Sakaguchi, and N. Minato Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation Transpl Immunol 17 2007 94 97 (Pubitemid 46240888)
60. A.J. Demetris, J.G. Lunz 3rd, P. Randhawa, T. Wu, M. Nalesnik, and A.W. Thomson Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective Transpl Int 22 2009 120 141
61. M. Yoshitomi, T. Koshiba, H. Haga, Y. Li, X. Zhao, and D. Cheng Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation Transplantation 87 2009 606 614
62. G. Orlando, T. Manzia, L. Baiocchi, A. Sanchez-Fueyo, M. Angelico, and G. Tisone The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months Transpl Immunol 20 2008 43 47
63. J.A. Pons, P. Ramirez, B. Revilla-Nuin, D. Pascual, A. Baroja-Mazo, and R. Robles Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients Clin Transpl 23 2009 329 336
64. S. Feng, U.D. Ekong, S.J. Lobritto, A.J. Demetris, J.P. Roberts, and P. Rosenthal Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants JAMA 307 2012 283 293
65. F. Bohne, M. Martinez-Llordella, J.J. Lozano, R. Miquel, C. Benitez, and M.C. Londono Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation J Clin Invest 122 2012 368 382
66. C. Benitez, J.J. Lozano, and M. Marínez-Llordella Use of transcriptional biomarkers to identify liver transplant recipients who can succesfully discontinue immunosuppressive therapy Am J Transplant 10 2010 Abstract 517
67. C. Benitez, M.C. Londoño, R. Miquel, T. Manzia, J.G. Abraldes, and J.J. Lozano Prospective multi-center clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients Hepatology 2013 10.1002/hep.26426 [Epup ahead of print]
68. A. Shaked, S. Feng, J. Punch, J. Reyes, J. Levitsky, and G. Klintmalm Lessons learned from the ITN030ST immunosuppression withdrawal (ISW) trial in liver transplant recipients Liver Transpl 17 2011 S84 Abstract # O-18
69. M. Berenguer Hot topic in hepatitis C virus research: the type of immunosuppression does not matter Liver Transpl 17 2011 S24 S28
70. B. Roche, and D. Samuel Risk factors for hepatitis C recurrence after liver transplantation J Viral Hepat 14 2007 89 96 (Pubitemid 47624117)
71. J.F. Trotter Hot-topic debate on hepatitis C virus: the type of immunosuppression matters Liver Transpl 17 2011 S20 S23
72. X. Forns, and M. Navasa Cyclosporine A or tacrolimus for hepatitis C recurrence? An old debate Am J Transplant 11 2011 1559 1560
73. M. Berenguer, V. Aguilera, M. Prieto, F. San Juan, J.M. Rayon, and S. Benlloch Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression J Hepatol 44 2006 717 722
74. T.M. Manzia, R. Angelico, L. Baiocchi, L. Toti, P. Ciano, and G. Palmieri The Tor Vergata weaning of immunosuppression protocols in stable hepatitis C virus liver transplant patients: the 10-year follow-up Transpl Int 26 2013 259 266
75. S.A. Farkas, A.A. Schnitzbauer, G. Kirchner, A. Obed, B. Banas, and H.J. Schlitt Calcineurin inhibitor minimization protocols in liver transplantation Transpl Int 22 2009 49 60
76. J. Lerut, E. Bonaccorsi-Riani, P. Finet, and P. Gianello Minimization of steroids in liver transplantation Transpl Int 22 2009 2 19
77. L. Penninga, A. Wettergren, A.W. Chan, D.A. Steinbruchel, and C. Gluud Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients Cochrane Database Syst Rev 3 2012 CD008852
78. J. Leventhal, M. Abecassis, J. Miller, L. Gallon, K. Ravindra, and D.J. Tollerud Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation Science Transl Med 4 2012 124 128